MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication

Similar documents
STN: BL /5234 HSTCL PAS April 14, 2009

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) What is the most important information I should know about REMICADE?

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab)

SYMPTOM CONTROL? PEDIATRICS

AVONEX Interferon beta-1a

Enoxaparin (Lovenox )

Sovaldi Pegasys Ribavirin

All medicines have risks and benefits. Your doctor has weighed the risks of you using REMICADE against the benefits it is expected to have for you.

LEARN. about. Please see Important Safety Information on pages 3-5 and enclosed full Prescribing Information.

AVONEX. What is in this Leaflet. What AVONEX is used for. Before you use AVONEX. Interferon beta-1a. Consumer Medicine Information

NEUPOGEN Filgrastim (rbe)

Package leaflet: Information for the user. Synagis 100 mg/ml solution for injection Active substance: palivizumab

Treatment: Nutrition and Medication

Iron Deficiency Anemia

Filgrastim 300 mcg in 0.5 ml and 480 mcg in 0.5 ml (prefilled syringes) and 300 mcg in 1 ml (vials) solution for injection

Material Safety data sheet

Zepatier (Elbasvir/Grazoprevir) & Ribavirin Treatment Agreement

Information and resources for African Americans living with multiple myeloma and their caregivers

NEW PATIENT REGISTRATION FORM

Iron Deficiency Anemia Information for patients and families

Learn more about why severe RSV disease APPROVED USE

Patient Information NEUPOGEN (nu-po-jen) (filgrastim) injection What is NEUPOGEN? NEUPOGEN is a man-made form of granulocyte colony-stimulating

A GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE

Disease Prevention and Health Maintenance

Riastap 1 g Powder for solution for injection / infusion Human fibrinogen

NEUPOGEN. (Filgrastim) Information for Patients and Caregivers

Package leaflet: Information for the patient. Ceftazidim Sandoz, 2.0 g, powder for solution for injection

For a full listing of nonmedicinal ingredients see Part 1 of the product monograph. PART III: CONSUMER INFORMATION

HOURS CALL 117

Package leaflet: Information for the user. HUMAN ALBUMIN BAXALTA 200 g/l Solution for Infusion. Human albumin

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Students should be able to explain how the spread of diseases can be reduced or prevented.

Myeloma XII (ACCoRd) Myeloma Infosheet Series. Clinical trials and novel drugs Infoline:

FREQUENTLY ASKED QUESTIONS ABOUT EBOLA VIRUS DISEASE

Enoxaparin in Pregnancy. An information leaflet for women who have been advised that they may need Enoxaparin treatment

Frequently Asked Questions About Ebola Virus Disease

Document number (version): RMP.NUS (3.0) Page 63 of 95

PATIENT REGISTRATION

National MS Society Information Sourcebook

Health Effects Associated with Stack Chemical Emissions from NYS Natural Gas Compressor Stations:

Alagille Syndrome. A Guide. An explanation of what Alagille syndrome is, its causes, diagnosis and treatment

PART III: CONSUMER INFORMATION

Avoiding Ebola. Thare Machi Education, PO Box 4040, Leamington Spa, CV32 5YJ, UK

Scottish Medicines Consortium

Elemental Metals and Toxic Effects. Heavy Metals

PROTECT YOURSELF PROTECT YOUR FAMILY PROTECT YOUR COMMUNITY from Ebola

Riastap (fibrinogen concentrate, human) Public Summary of Risk Management Plan (Extract from the EU Risk Management Plan Version 3.

Science in the News: Carbon Monoxide Poisoning

Knocking Over Pollutants

GUIDELINES FOR EMPLOYEE S HEALTH - AN USEFUL TOOL FOR WORKPLACE HEALTH PROTECTION

Address: Age: DOB: Occupation: Referred by: Primary Reason for Visit: Other Concerns: Number of Children: Ages:

Package leaflet: Information for the user. Remicade 100 mg powder for concentrate for solution for infusion Infliximab

INSURANCE INFORMATION

Primary Care Guideline for the Management of People Concerned About/Potentially Exposed to Ebola. Provincial Ebola Response Task Force Nov.

Pesticide Exposures for People in Agricultural Areas. 7 th March 2007 Georgina Downs UK Pesticides Campaign

You ve Got the POWER! What You Should Know About Clinical Trials

Consent Forms Wendy Doggett, June 28, 2012

Greater Monmouth Neurology P.C. 130 Maple Avenue Suite 1-A Red Bank NJ, Phone Fax Please Print Clearly

The MS Disease- Modifying Medications. General information

Introduction to Lassa fever

Economic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with

Coordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin

By Wilma Subra Subra Company P. O. Box 9813 New Iberia, LA

Oxford Newborn Care Unit. Palivizumab (Synagis ) for RSV Infection Information for parents and carers

Compliance vs. Communication in Clinical Trial Registries

SAFETY DATA SHEET. Non-hazardous in accordance with international standards for workplace safety

Donor Informed Consent to Participate in Research

British Midland Regional Limited Cabin Crew Employment Application Form

Post Evaluation Medical Technology 2005

KNOWN HAZARDS UNDER 29 CFR

Package leaflet: Information for the user. Enoxaparin Becat 10,000 IU (100 mg)/1 ml solution for injection in pre-filled syringe.

Package leaflet: Information for the user. AVONEX 30 micrograms/0.5 ml solution for Injection (Interferon beta-1a) Pre-filled syringe

Ebola Frequently Asked Questions

New Findings Show Avoiding GMOs Improves Health

The Latest Therapies for MS: Weighing Respective Benefits and Risks

SULFANILAMIDE Page 1 of 8

APPLICATION FOR EMPLOYMENT AS AN INTERIM MANAGER

Safety Data Sheet European Format

Atrazine. What happens to atrazine when it enters the environment?

Polychlorinated Biphenyls (PCBs)

Project Title - Mystery Client Study. Mystery client study to assess quality of care among patients seeking treatment for febrile illness

Reduce. Talk. Avoid. The UK s first-ever National Clean Air Day is a chance for people from all over the country to create cleaner air for everyone

Rodale s DTC th YEAR DTC STUDY

SCIENTIFIC DISCUSSION

MATERIAL SAFETY DATA SHEET. 1. Product and Company Identification

Stem Cell Uses and FDA Regulation

Does this topic relate to the work the crew is doing? If not, choose another topic.

Copper. Public Health Statement for CAS# December 1990

Clinical trials patient-education brochure

Media That Delivers Media Kit

Package leaflet: Information for the user. Neupogen 30 MU (0.3 mg/ml) solution for injection filgrastim

Learning about Clinical Trials

REMICADE can help keep symptoms under control help make it last

Health Education Recipe: Body Mapping

LET S EXPLORE OUR BODY SYSTEMS. Esther Vilar Garcés

MATERIAL SAFETY DATA SHEET

By: Wilma Subra Subra Company

Program Guide PATIENT

Re: Docket No. FDA-2009-N-0295: Providing Effective Information to Consumers about Prescription Drug Risks and Benefits.

Ask your surgeon for more information about Natrelle and visit GummyImplants.com

Transcription:

MEDICATION GUIDE RIBAVIRIN TABLETS Rx Only Read this Medication Guide carefully before you start taking ribavirin tablets and read the Medication Guide each time you get more ribavirin tablets. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment. What is the most important information I should know about ribavirin tablets? 1. Ribavirin tablets may cause birth defects or death of an unborn child. Therefore, if you are pregnant or your partner is pregnant or plans to become pregnant, do not take ribavirin tablets. Female patients and female partners of male patients being treated with ribavirin tablets must not becomepregnant during treatment and for 6 months after treatment has stopped. During this time you must have pregnancy tests that show you are not pregnant. You must also use 2 effective forms of birth control during therapy and for 6 months after stopping therapy. Male patients should use a condom with spermicide as one of the two forms. If pregnancy occurs, report the pregnancy to your healthcare provider right away. (See " What should I avoid while taking ribavirin tablets? ") If you or a female sexual partner becomes pregnant, you should tell your healthcare provider. There is a Ribavirin Pregnancy Registry that collects information about pregnancy outcomes of female patients and female partners of male patients exposed to ribavirin. You or your healthcare provider are encouraged to contact the Registry at 1-800-593-2214. 2. Ribavirin tablets can cause a dangerous drop in your red blood cell count. Ribavirin tablets can cause anemia, which is a decrease in the number of red blood cells. This can be dangerous, especially if you have heart or breathing problems. This may cause a worsening of heart (cardiovascular) or circulatory problems. Some patients may get chest pain and rarely, a heart attack. Patients with a history of heart disease have the highest chance of this. Tell your healthcare provider, before taking ribavirin tablets if you have or have ever had any heart or breathing problems. Your healthcare provider should check your red blood cell count before you start treatment with ribavirin tablets and often during the first 4 weeks of treatment. Your red blood cell count may be done more often if you have any heart or breathing problems. 3. Do not take ribavirin tablets alone to treat hepatitis C virus infection. Ribavirin tablet does not treat hepatitis C virus infections by itself. Ribavirin tablets should be used in combination with peginterferon alfa-2a to treat continuing (chronic) hepatitis C virus infections. You should read the Medication Guide for peginterferon alfa-2a because it has additional important information about treatment that is not covered in this Medication Guide. Your healthcare provider or pharmacist should give you a copy of the peginterferon alfa-2a Medication Guide. What is ribavirin tablet? Ribavirin tablet is the antiviral medicine containing ribavirin. It is used in combination with a medicine called peginterferon alfa-2a to treat some adults with chronic hepatitis C whose liver still works normally, and who have not been treated before with a medicine called an interferon alpha. It is not known how ribavirin tablets and peginterferon alfa-2a work together to fight hepatitis C virus infections. It is not known if treatment with ribavirin tablets and peginterferon alfa-2a combination therapy can cure hepatitis C or if it can prevent liver damage (cirrhosis), liver failure or liver cancer that is caused by hepatitis C virus infections. It is not known if treatment with ribavirin tablets and peginterferon alfa-2a combination therapy will prevent an infected person from spreading the hepatitis C virus to another person.

Treatment with ribavirin tablet has not been studied in children under 18 years of age. Who should not take ribavirin tablets? Do not use ribavirin tablets if: You are a female and you are pregnant or plan to become pregnant during treatment or during the 6 months after your treatment has ended. (See " What is the most important information I should know about ribavirin tablets? " and " What should I avoid while taking ribavirin tablets?") You are a male patient with a female sexual partner who is pregnant or plans to become pregnant at any time while you are being treated with ribavirin tablets or during the 6 months after your treatment has ended. (See "What is the most important information I should know about ribavirin tablets?" and "What should I avoid while taking ribavirin tablets?") You are breast feeding. We do not know if ribavirin tablets can pass through your milk and if it can harm your baby. You will need to choose either to breast feed or take ribavirin tablets, but not both. You have a liver disease called autoimmune hepatitis (hepatitis caused by your immune system attacking your liver). You have unstable or severe liver disease. You are allergic to any of the ingredients in ribavirin tablets. The active ingredient in ribavirin tablets is ribavirin. See the end of this Medication Guide for a list of all the ingredients in ribavirin tablets. Tell your healthcare provider before starting treatment with ribavirin tablets in combination with peginterferon alfa-2a (see also the peginterferon alfa-2a Medication Guide) if you have any of the following medical conditions: mental health problems, such as depression or anxiety: Ribavirin tablets and peginterferon alfa-2a combination therapy may make them worse. Tell your healthcare provider if you are being treated or had treatment in the past for any mental problems, including depression, thoughts of ending your life (suicidal thoughts) or a feeling of loss of contact with reality, such as hearing voices or seeing things that are not there (psychosis). Tell your healthcare provider if you take any medicines for these problems. high blood pressure, heart problems or have had a heart attack. Ribavirin tablets may worsen heart problems such as high blood pressure, increased heart rate, and chest pain. Tell your healthcare provider if you have or had a heart problem. Patients who have had certain heart problems should not take ribavirin tablets. blood disorders, including anemia (low red blood cell count), thalassemia (Mediterranean anemia) and sickle-cell anemia. Ribavirin tablets can reduce the number of red blood cells you have. This may make you feel dizzy or weak and could worsen any heart problems you might have. kidney problems. If your kidneys do not work properly, you may have worse side effects from ribavirin tablets treatment and require a lower dose. liver problems (other than hepatitis C virus infection). organ transplant, and you are taking medicine that keeps your body from rejecting your transplant (suppresses your immune system). thyroid disease. Ribavirin tablets and peginterferon alfa-2a combination therapy may make your thyroid disease worse or harder to treat. Ribavirin tablets and peginterferon alfa-2a treatment may be stopped if you develop thyroid problems that cannot be controlled by medicine. have or had drug or alcohol addiction or abuse. cancer. infection with hepatitis B virus. diabetes. Ribavirin tablets and peginterferon alfa-2a combination therapy may make your diabetes worse or harder to treat. past interferon treatment for hepatitis C virus infection that did not work for you. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins or herbal supplements. Some medicines can cause serious side effects if taken while you

also take ribavirin tablets. Some medicines may affect how ribavirin tablets work or ribavirin tablets may affect how your other medicines work. Be especially sure to tell your healthcare provider if you take any medicines to treat HIV. For more information see the peginterferon alfa-2a Medication Guide. How should I take ribavirin tablets? Your healthcare provider will determine the right dose of ribavirin tablets based on your weight. Take ribavirin tablets 1 time in the morning and 1 time at night (2 times a day). Take ribavirin tablets the same 2 times each day. Take ribavirin tablets with food. It is very important to follow your dosing schedule and your healthcare provider's instructions on how to take your medicines. Take ribavirin tablets for as long as it is prescribed, and do not take more than your healthcare provider prescribes. If you miss a dose of ribavirin tablets and remember the same day, take the missed dose as soon as you remember. If the whole day has passed, ask your healthcare provider what to do. Do not take 2 doses at the same time. Your healthcare provider may adjust your dose of ribavirin tablets based on blood tests that show your response to treatment and side effects you may have. Females taking ribavirin tablets or female sexual partners of male patients taking ribavirin tablets must have a pregnancy test: before treatment begins every month during treatment for 6 months after treatment ends to make sure there is no pregnancy It is also important not to use other ribavirin medicines without talking to your healthcare provider. Please see the peginterferon alfa-2a Medication Guide for the proper use of peginterferon alfa-2a injection. What should I avoid while taking ribavirin tablets? Avoid the following during ribavirin tablets treatment: Do not get pregnant. If you or your sexual partner get pregnant during treatment with ribavirin tablets or in the 6 months after treatment ends, tell your healthcare provider right away. (See " What is the most important information I should know about ribavirin tablets? ")Talk with your healthcare provider about birth control methods and how to avoid pregnancy. You must use extreme care to avoid pregnancy during and for 6 months after treatment in female and male patients. Do not take ribavirin tablets alone to treat your hepatitis C virus infection. Ribavirin tablets should be used in combination with peginterferon alfa-2a to treat chronic hepatitis C virus infections. (See " What is the most important information I should know about ribavirin tablets? ") Do not breast feed. Ribavirin tablets may pass through your milk and may harm your baby. Do not drink alcohol, including beer, wine, and liquor. This may make your liver disease worse. Do not drive or operate machinery if ribavirin tablet makes you feel tired, dizzy or confused. Do not take other medicines unless your healthcare provider knows about them. Take only medicines prescribed or approved by your healthcare provider. These include prescription and non-prescription medicines, vitamins or herbal supplements. Talk to your healthcare provider before starting any new medicine. What are the possible side effects of ribavirin tablets? The most serious possible side effects of ribavirin tablets are:

Harm to unborn children. Ribavirin tablets may cause birth defects or death of an unborn child. (For more details, see " What is the most important information I should know about ribavirin tablets? ") Anemia. Anemia is a reduction in the number of red blood cells you have. Anemia can be dangerous, especially if you have heart or breathing problems. Tell your healthcare provider right away if you feel tired, have chest pain or shortness of breath. These may be signs of low red blood cell counts. Liver Problems. Some patients may develop worsening of liver function. Some of the symptoms may include stomach bloating, confusion, brown urine, and yellow eyes. Tell your healthcare provider immediately if any of these symptoms occur. Call your healthcare provider right away if you have any of the following symptoms. They may be signs of a serious side effect of ribavirin tablets and peginterferon alfa-2a treatment. trouble breathing hives or swelling chest pain severe stomach pain or low back pain bloody diarrhea or bloody stools (bowel movements). These may look like black tar. bruising or unusual bleeding change in your vision high fever (temperature greater than 100.5 F) you have psoriasis (a skin disease) and it gets worse you become very depressed or think about suicide (ending your life) Skin rash can occur in patients taking peginterferon alfa-2a. In some patients a rash can be serious. If you develop a rash with fever, blisters, or sores in your mouth, nose or eyes or conjunctivitis (red or inflamed eyes, like "pink eye"), stop using peginterferon alfa-2a and call your doctor right away. The most common side effects of ribavirin tablets are likely to be the same as for other ribavirin products. These are: feeling tired nausea and appetite loss rash and itching cough These are not all the possible side effects of ribavirin tablets treatment. For more information, ask your doctor or pharmacist and see the peginterferon alfa-2a Medication Guide. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA- 1088. What should I know about hepatitis C infection? Hepatitis C infection is a disease caused by a virus that infects the liver. Hepatitis C is more serious for some people than others. Most people who get hepatitis C carry the virus in their blood for the rest of their lives. Most of these people will have some liver damage, but many do not feel sick from the disease. In some people, the liver becomes badly damaged and scarred. This is called cirrhosis. Cirrhosis can cause the liver to stop working. Some people may get liver cancer or liver failure from the hepatitis C virus. Hepatitis C virus is spread from one person to another by contact with an infected person's blood. You should talk to your healthcare provider about ways to prevent you from infecting others. How should I store ribavirin tablets? Store between 20-25 C (68-77 F). Please refer to the peginterferon alfa-2a Medication Guide for storage information about peginterferon alfa-2a injection.

General information about the safe and effective use of ribavirin tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ribavirin tablets for a condition for which it was not prescribed. Do not give ribavirin tablets to other people, even if they have the same symptoms that you have. This Medication Guide summarizes the most important information about ribavirin tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about ribavirin tablets that is written for healthcare professionals. What are the ingredients in ribavirin tablets? Active Ingredient: ribavirin Inactive Ingredients: crospovidone, hypromellose, iron oxide red, iron oxide yellow, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, silicon dioxide, talc and titanium dioxide. This Medication Guide has been approved by the US Food and Drug Administration. Manufactured by: Cadila Healthcare Ltd. Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA Inc. Princeton, NJ 08534 Repackaged by: American Health Packaging Columbus, Ohio 43217 2013597 8015065/0609